Skip to main content

Table 7 Comparison of Tsc2+/- mTOR inhibitor trials

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

mTOR inhibitor

Total drug dose (per mouse)

Schedule

% Reduction in kidney tumors

Study

Rapamycin

19.2 mg

Part one: 8 mg/kg daily × 1 month

94.5%*

This study

  

Part two: 16 mg/kg weekly × 5 months

  
  

Part three: 8 mg/kg daily × 1 month

  

CCI-779

9.6 mg

8 mg/kg daily × 2 months

63%*

Messina et al. 2007

   

64%**

 

CCI-779

4.32 mg

4 mg/kg 3 times a week × 3 months

83.6%**

Lee et al. 2005

  1. * Kidney tumor score
  2. **Kidney tumor number
Back to article page

BMC Pharmacology

ISSN: 1471-2210